Impact of Emicizumab on Coagulation Potential in Plasma From Healthy Women and Carriers of Haemophilia A During Late Pregnancy
These findings ex vivo indicated that Emi at clinically relevant concentrations does not meaningfully enhance the hypercoagulable state characteristic of late pregnancy. In vivo studies are required to confirm the safety of maternal prophylaxis.
Authors
- Naruto Shimonishi (ORCID: https://orcid.org/0000-0002-0157-5215)
- Kana Sasai
- Fuminori Kimura (ORCID: https://orcid.org/0000-0002-9840-4227)
- Tetsuhiro Soeda
- Masahiro Takeyama (ORCID: https://orcid.org/0000-0002-9348-9815)
- Yuto Nakajima (ORCID: https://orcid.org/0000-0001-5422-2782)
- Kenichi Ogiwara (ORCID: https://orcid.org/0000-0002-3046-6915)
- Mitsumasa Osuna
- Suguru Harada
- Shoko Furukawa
- Keiji Nogami
Institutions
- Osaka National Hospital (JP)
- Chugai Pharma (United States) (US)
- Nara Medical University (JP)
Publication Details
- Journal
- Haemophilia
- Published
- 2026-03-23
- DOI
- https://doi.org/10.1111/hae.70269
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00